| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANNABIS BIOSCIENCE INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| Mo | Cannabis Bioscience International Holdings: Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement | 185 | Newsfile | Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today... ► Artikel lesen | |
| 15.06. | Cannabis Bioscience International Holdings: CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research | 257 | Newsfile | Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter... ► Artikel lesen | |
| 08.06. | Cannabis Bioscience International Holdings: CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers | 235 | Newsfile | Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced... ► Artikel lesen | |
| 01.06. | Cannabis Bioscience International Holdings: CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation | 181 | Newsfile | Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic... ► Artikel lesen | |
| 16.04. | Cannabis Bioscience International Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.04. | Cannabis Bioscience International Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 19.02. | Cannabis Bioscience International Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.01. | Cannabis Bioscience International Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 12.01. | Cannabis Bioscience International Holdings: CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence | 230 | Newsfile | Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced... ► Artikel lesen | |
| 05.01. | Cannabis Bioscience International Holdings: CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition | 274 | Newsfile | Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today... ► Artikel lesen | |
| 29.12.25 | Cannabis Bioscience International Holdings: CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways | 362 | Newsfile | Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today... ► Artikel lesen | |
| 22.12.25 | Cannabis Bioscience International Holdings: CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities | 304 | Newsfile | Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications... ► Artikel lesen | |
| 13.10.25 | Cannabis Bioscience International Holdings: CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery | 434 | Newsfile | Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its... ► Artikel lesen | |
| 06.10.25 | Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook | 338 | Newsfile | Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on... ► Artikel lesen | |
| 29.09.25 | Cannabis Bioscience International Holdings: CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center | 262 | Newsfile | Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,000 | 0,00 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| MERCK KGAA | 145,65 | -0,92 % | DZ BANK stuft MERCK KGAA auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Merck KGaA auf "Kaufen" mit einem fairen Wert von 153 Euro belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,390 | 0,00 % | Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? | ||
| JOURNEY MEDICAL | 6,620 | 0,00 % | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,730 | 0,00 % | Canaccord reiterates TriSalus stock Buy rating after KOL event | ||
| NOVO NORDISK | 42,185 | +0,15 % | Novo Nordisk macht Druck: Wird das der ersehnte Befreiungsschlag? | Die Aktie des dänischen Pharmakonzerns Novo Nordisk ringt um Dynamik. Das Ende der Korrektur und die untere Trendwende scheinen greifbar. Gelingt es der Pharmaaktie nach der langwierigen Korrektur,... ► Artikel lesen | |
| ELI LILLY | 1.065,00 | +0,49 % | Why Eli Lilly Stock Jumped to a New All-Time High Today | ||
| LB PHARMACEUTICALS | 31,770 | -0,47 % | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | ||
| SHUTTLE PHARMACEUTICALS | 3,970 | -1,24 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site | Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,550 | +0,49 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| PFIZER | 21,280 | -0,26 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Pfizer von 35 auf 34 US-Dollar gesenkt, aber die Einstufung auf "Buy" belassen. Die Be6A-Lungenkrebsstudie (NSLC) mit Sigvotatug... ► Artikel lesen | |
| KARDIGAN | 23,450 | -0,64 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 35,660 | -0,11 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| ABBVIE | 220,50 | -0,27 % | Check: 5 Käufe für die Woche | Micron: Vor Zahlen, Abbvie: Übernahmen & OHB: Dax-Kandidat | Check: 5 Käufe für die Woche | Micron: Vor Zahlen, Abbvie: Übernahmen & OHB: Dax-Kandida ► Artikel lesen | |
| DOCMORRIS | 8,940 | -0,17 % | Adhoc: DocMorris AG: DocMorris kündigt beschleunigte Umsetzung der «AI-First»-Strategie an; positiver Kosteneffekt von mindestens CHF 15 Mio. pro Jahr | DocMorris AG / Schlagwort(e): Strategische Unternehmensentscheidung
DocMorris kündigt beschleunigte Umsetzung der «AI-First»-Strategie an; positiver Kosteneffekt von mindestens CHF 15 Mio.... ► Artikel lesen |